GlassScriptPhysician profile
Pavana Beerelli
NPI 1891957031
$60,817.11
in general payments reported to CMS, 2019-2025
37 companies · $19K in 2025
The $19K reported for 2025 was more than what 91% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $735 · 2021: $1,687 · 2022: $12K · 2023: $9,725 · 2024: $16K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $7,452 · Travel and Lodging: $3,430 · Consulting Fee: $171 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,745.00 |
| Food and Beverage | $7,451.80 |
| Travel and Lodging | $3,429.89 |
| Consulting Fee | $170.92 |
| Education | $126.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $28,860.81 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Optinose US, INC. | $20,138.00 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,410.33 | 2019-2025 | Dupixent |
| Amgen INC. | $1,363.58 | 2020-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $1,063.80 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Pfizer INC. | $1,040.22 | 2020-2025 | |
| Glaxosmithkline, LLC. | $914.72 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $887.39 | 2019-2025 | |
| Csl Behring | $713.14 | 2019-2025 | Hizentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $674.43 | 2019-2025 | |
| Abbvie INC. | $560.10 | 2021-2025 | Rinvoq |
| Incyte Corporation | $361.61 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.51 | 2019-2023 | Spiriva Respimat |
| Pharming Healthcare, INC. | $338.02 | 2019-2024 | Ruconest |
| Genentech USA, INC. | $328.70 | 2019-2025 | Xolair |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $284.65 | 2019-2025 | Xembify |
| Kaleo, INC. | $214.39 | 2019-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $201.54 | 2022-2025 | Orladeyo |
| Adma Biomanufacturing LLC | $170.92 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $155.95 | 2021-2022 | |
| Shire North American Group INC | $97.99 | 2019 | |
| Alk-Abello, INC | $87.16 | 2019-2022 | |
| Leo Pharma INC. | $84.29 | 2022-2023 | Adbry |
| Ars Pharmaceuticals Operations, INC. | $67.66 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $66.70 | 2023-2025 | Ryaltris |
| Bio Products Laboratory USA, INC. | $57.20 | 2023 | Gammaplex, Coagadex |
| Phadia US INC. | $53.45 | 2021-2024 | Immunocap |
| Blueprint Medicines Corporation | $48.22 | 2023 | Ayvakit |
| Galderma Laboratories, L.P. | $35.24 | 2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $32.01 | 2022 | |
| Uswm, LLC | $28.53 | 2021 | |
| Circassia INC. | $25.89 | 2019-2021 | |
| Kedrion Biopharma, INC. | $23.61 | 2024 | Koate, Gammaked, Kedrab |
| Gc Biopharma USA, INC. | $22.47 | 2025 | Alyglo |
| Lilly USA, LLC | $20.82 | 2025 | Ebglyss |
| Cycle Pharmaceuticals INC | $18.60 | 2025 | Sajazir |
| Sunovion Pharmaceuticals INC. | $18.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavana Beerelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.